Genzyme to Acquire Remaining 78% of Focal

(Cambridge, MA, USA) has agreed to acquire Focal, Inc. (Lexington, MA, USA) and merge its operations with Genzyme's Biosurgery unit. Genzyme currently owns 22% of Focal and will purchase the remaining 78% in an exchange of stock.

Genzyme Biosurgery will also gain worldwide rights to market FocalSeal-L, a synthetic liquid polymer used to seal air leaks that develop during lung surgery. In addition, the company will acquire a pipeline of biomaterials being developed for other types of surgeries, including FocalSeal-S for use in sealing the dura following brain or spinal surgery. Genzyme Corp. invested US$15 million in Focal in exchange for North American marketing rights to FocalSeal-L.

"Obtaining Focal's extensive intellectual property and promising product pipeline will expand our leadership position in the emerging field of surgical biomaterials,” said Duke Collier, president of Genzyme Biosurgery.




Related Links:
Genzyme